IndraLab

Statements


| 21

sparser
"Of these, RFPL1S ( p = 0.0001), PPP1R26-AS1 ( p = 0.03), RP11-439E19.3 ( p = 1.24 × 10 –6 ), CASC15 ( p = 1.6 × 10 –7 ), AC004540.5 ( p = 0.0002), and CTD-2881E23.2 ( p = 1.6 × 10 –9 ) were found to be significantly upregulated ( xref ), while USP3-AS1 ( p = 1.78 × 10 –6 ), CHRM3-AS2 ( p = 0.003) and RP6-99M1.2 ( p = 0.002) were significantly downregulated ( xref )."

sparser
"Of these, one was upregulated, PPP1R26-AS1 ( p = 5.2 × 10 –4 , number of samples with high expression = 14, number of samples with low expression = 74), and the other was downregulated, USP3-AS1 ( p = 0.019, number of samples with high expression = 42, number of samples with low expression = 46) ( xref )."

sparser
"USP3-AS1 is a negative regulator of mitophagy and the regulatory effect is USP30-independent."

sparser
"After cross-sectional analysis, three lncRNAs, CASC15 , PPP1R26-AS1 and USP3-AS1 , were found to be significantly altered in different datasets compared to other lncRNAs ( xref )."

sparser
"In our study, the expression of MALAT1, USP3-AS1, and LINC-PINT was associated with worse overall survival in breast cancer patients."

sparser
"USP3-AS1 has also been reported as a potential biomarker for neuroblastoma pathogenesis studies xref ."

sparser
"b Overall survival (OS) as a function of MALAT1, USP3-AS1, and LINC-PINT expression in breast cancer."

sparser
"This database revealed that the expression of three lncRNAs was altered significantly in neuroblastoma samples; two were upregulated, namely CASC15 ( p < 0.0001, unpaired two-tailed t -test with Welch’s correction) and PPP1R26-AS1 ( p < 0.05, unpaired two-tailed t -test with Welch’s correction), and one was downregulated, USP3-AS1 ( p < 0.0001, unpaired two-tailed t -test with Welch’s correction) ( xref )."

sparser
"Interestingly, the PPP1R26-AS1- associated gene PPP1R26 was differentially expressed in all of the conditions [Tumor vs. MNCs, DTCs vs. MNCs, and DTCs (relapsed) vs. MNCs (relapsed)], whereas USP3-AS1 -associated coding genes USP3 and FBXL22 were differentially expressed only in primary neuroblastoma tumor."

sparser
"Interestingly, the expression of MALAT1, USP3-AS1, and LINC-PINT was associated with worse overall survival in breast cancer patients (Fig. xref )."

sparser
"The PRL and SOX4 protein-coding genes are associated with CASC15 , PPP1R26 is associated with PPP1R26-AS1 , and USP3 and FBXL22 are associated with USP3-AS1 ."

sparser
"However, the association or any functional analysis of the third of the identified lncRNAs, USP3-AS1 , has not been reported with any cancer."

sparser
"Interestingly, lncRNA profiling of MALAT1-depleted TNBC also revealed a number of altered lncRNAs in response to MALAT1 deletion, suggesting a reciprocal relationship between MALAT1 and a number of lncRNAs, including NEAT1, USP3-AS1, and LINC-PINT, in TNBC."

sparser
"USP3-AS1 has also been reported as a potential biomarker for neuroblastoma pathogenesis studies38."

sparser
"They reported up-regulation of RFPL1S, PPP1R26-AS1, RP11-439E19.3, CASC15, AC004540.5, and CTD-2881E23.2 while down-regulation of USP3-AS1, CHRM3-AS2 and RP6-99M1.2 in tumor cells compared with the corresponding non-tumor mononuclear cells isolated from bone marrow (MNCs)."

sparser
"After this cross-sectional study, we were able to identify three significant lncRNAs, CASC15 , PPP1R26-AS1 , and USP3-AS1 , which could serve as potential biomarkers in clinical studies of neuroblastoma pathogenesis."

sparser
"Elevated expression of MALAT1, USP3-AS1, and LINC-PINT correlated with worse clinical outcomes in BC patients."

sparser
"Interestingly, the expression of MALAT1, USP3-AS1, and LINC-PINT was associated with worse overall survival in breast cancer patients (Fig. 7b)."

sparser
"We have identified five lncRNA-associated coding partners that are near (around the 5 kb region) to cross-validated lncRNAs CASC15, PPP1R26-AS1 , and USP3-AS1 , which belong to different classes/biotypes of lncRNAs."

sparser
"They suggested CASC15, PPP1R26-AS1, and USP3-AS1 lncRNAs as putative markers in clinical investigations in this type of pediatric cancer ( xref )."

sparser
"Three of these lncRNA candidates, USP3-AS1, LINC00877, and AC009312.1, were validated to have reduced expression in metastatic compared to non-metastatic PCPGs."